Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

ER - Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

Company: Oncoinvent ASA Date: 2025-08-27 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft

 Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

# Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian  

cancer with a strong focus on advancing the program and maximizing recruitment.  

  

Highlights for the first half of 2025:  

  

Radspherin®  

  

.             Positive final data from Phase1/2a trial in colorectal cancer  

patients  

  

.             Positive interim 18-months data from Phase1 trial in ovarian  

cancer patients  

  

.             Positive read-out of safety lead-in cohort and opening of  

randomized part of Phase 2 trial in ovarian cancer patients  

  

.             Regulatory approvals for additional sites for the randomized Phase  

2 trial in ovarian cancer, with expected onboarding before end of 2025  

  

Corporate  

  

.             Operating expenses reduced by 28% versus last year  

  

.             Merger with BerGenBio  

  

.             Fully guaranteed rights issue of NOKm 130  

  

CEO Øystein Soug and CFO Tore Kvam will present the results for the first half  

of 2025 at a webcast available at  

https://channel.royalcast.com/landingpage/hegnarmedia/20250827\_3/, Wednesday 27  

August at 08:00 CEST. The presentation and Q&A will be held in English. A  

recording of the webcast will be made available on our website shortly after the  

presentation.  

  

About Oncoinvent  

  

Oncoinvent is a clinical-stage biotechnology company developing novel  

radiopharmaceutical therapies against cancer. The lead product candidate,  

Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting  

micro-metastases post-surgery, harnessing the benefits of modern  

radiopharmaceuticals without the complexities of biological targeting.  

Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical  

development program in two indications. In addition to a recently finalized  

phase 1/2a trial in colorectal cancer, Oncoinvent is running two trials in  

ovarian cancer: one phase 1 trial and one randomized phase 2 trial in the US, UK  

and Europe. Preliminary clinical efficacy data are highly encouraging, and no  

serious toxicity or safety concerns have been reported to date. The Oncoinvent  

team runs a state-of-the-art manufacturing facility to produce drug products for  

clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth  

Oslo.  

  

About Radspherin  

  

Radspherin® is an investigational radiopharmaceutical designed for the local  

treatment of cancer that has spread to body cavities. It consists of calcium  

carbonate microparticles containing the radioactive material radium-224. The  

mode of action is the decay of radium-224 emitting alpha-particles, a highly  

potent form of ionizing radiation. Radspherin® is investigated in ongoing  

clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal  

cancer and it is administered intraperitoneally after surgical resection with  

removal of all macroscopic tumors.  

  

Forward-Looking Statements  

  

All statements other than statements of historical facts contained in this press  

release are forward-looking statements and are not a representation that  

Oncoinvent's plans, estimates, or expectations will be achieved. These forward  

\-looking statements represent Oncoinvent's expectations as of the date of this  

press release, and Oncoinvent disclaims any obligation to update the forward  

\-looking statements. These forward-looking statements are subject to known and  

unknown risks and uncertainties that may cause actual results to differ  

materially, including with respect to whether the results of clinical or other  

studies will support the use of our product offerings, the impact of results of  

such studies, our expectations of the reliability, accuracy and performance of  

our tests, or of the benefits of our tests and product offerings to patients,  

providers and payers.  

  

For further information, please contact:  

  

Øystein Soug, Chief Executive Officer  

Email: soug@oncoinvent.com  

  

Tore Kvam, Chief Financial Officer  

Email: kvam@oncoinvent.com

Chat with Filing

ER - Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

You're One Click Away From The Full Filing

Talk to a Data Expert